Massachusetts Institute of Technology

The Broad Institute, Inc.

Harvard College

The Rockefeller University

David Benjamin Turitz Cox

Feng Zhang

Omar O Abudayyeh

Jonathan S Gootenberg

Bernd Zetsche

Sangeeta N Bhatia

Patrick D Hsu

Le Cong

Ian Slaymaker

David Bikard

Fei Ran

Soumya Kannan

Neena Pyzocha

Charles F Rice

Luciano Marraffini

Neville Espi Sanjana

Eric S Lander

Linyi Gao

Randall Jeffrey Platt

Aaron Smargon

Matthias Heidenreich

Lukasz Swiech

Vyas Ramanan

Naomi Habib

Jonathan Strecker

Wenyan Jiang

Robert Schwartz

Amir Shlomai

David Olivier Bikard

Shauiliang Lin

The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA. Aspects of the invention in particular relate to Cpf1 mutants having altered PAM specificity.

CRISPR enzymes and systems with modified pam specificity

The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.

Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for HBV and viral diseases and disorders

The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA or RNA-targeting systems comprising a novel DNA or RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.

Crispr enzymes and systems

The invention provides for systems, methods, and compositions for targeting and editing nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a DNA-targeting Cpf1 protein, at least one guide molecule, and at least one adenosine deaminase protein or catalytic domain thereof.

Systems, methods, and compositions for targeted nucleic acid editing

The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.

Type VI CRISPR orthologs and systems

The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting Cas13b effector protein and at least one targeting nucleic acid component like a guide RNA or crRNA.

Cas13b orthologues CRISPR enzymes and systems

The disclosure provides for systems, methods, and compositions for targeting and editing nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a RNA-targeting Cas13 protein, at least one guide molecule, and at least one adenosine deaminase protein or catalytic domain thereof.

Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for genome editing

The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.

CRISPR-Cas component systems, methods and compositions for sequence manipulation

Growing community of inventors

Cambridge, MA, United States of America

David Benjamin Turitz Cox